- Home
- KIDS vs CRGX Comparison
KIDS vs CRGX Comparison
Compare KIDS & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- CRGX
- Stock Information
- Founded
- KIDS 2007
- CRGX 2021
- Country
- KIDS United States
- CRGX United States
- Employees
- KIDS N/A
- CRGX N/A
- Industry
- KIDS Medical/Dental Instruments
- CRGX
- Sector
- KIDS Health Care
- CRGX
- Exchange
- KIDS Nasdaq
- CRGX Nasdaq
- Market Cap
- KIDS 530.8M
- CRGX 190.0M
- IPO Year
- KIDS 2017
- CRGX 2023
- Fundamental
- Price
- KIDS $21.83
- CRGX $4.60
- Analyst Decision
- KIDS Buy
- CRGX Hold
- Analyst Count
- KIDS 7
- CRGX 7
- Target Price
- KIDS $35.71
- CRGX $5.33
- AVG Volume (30 Days)
- KIDS 126.1K
- CRGX 1.5M
- Earning Date
- KIDS 08-04-2025
- CRGX 08-11-2025
- Dividend Yield
- KIDS N/A
- CRGX N/A
- EPS Growth
- KIDS N/A
- CRGX N/A
- EPS
- KIDS N/A
- CRGX N/A
- Revenue
- KIDS $212,453,000.00
- CRGX N/A
- Revenue This Year
- KIDS $19.23
- CRGX $57.81
- Revenue Next Year
- KIDS $17.14
- CRGX N/A
- P/E Ratio
- KIDS N/A
- CRGX N/A
- Revenue Growth
- KIDS 31.28
- CRGX N/A
- 52 Week Low
- KIDS $19.52
- CRGX $3.00
- 52 Week High
- KIDS $35.99
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- KIDS 53.28
- CRGX 62.02
- Support Level
- KIDS $21.17
- CRGX $4.32
- Resistance Level
- KIDS $22.51
- CRGX $4.75
- Average True Range (ATR)
- KIDS 0.75
- CRGX 0.18
- MACD
- KIDS 0.09
- CRGX 0.03
- Stochastic Oscillator
- KIDS 73.23
- CRGX 77.17
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.